Ordering Recommendation

Evaluate the ability of a patient to produce antibody to pure protein vaccine after vaccination to rule out antibody deficiency.

Mnemonic
TETANUS
Methodology

Quantitative Multiplex Bead Assay

Performed

Sun-Sat

Reported

1-2 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube. "Post" specimen should be drawn 30 days after immunization.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL) "Pre" and "post" vaccine specimens can be submitted separately or together for testing; if shipped separately, "post" specimen must be received within 60 days of "pre" specimen. Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine".

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval

Antibody concentration of > 0.1 IU/mL is usually considered protective.

Interpretive Data

Responder status is determined according to the ratio of a one-month post-vaccination specimen to pre-vaccination concentration of tetanus IgG antibodies as follows:

1.  If the post-vaccination concentration is less than 1.0 IU, the patient is considered a nonresponder.
2.  If the post-vaccination concentration is greater than or equal to 1.0 IU, a patient with a ratio of less than 1.5 is a nonresponder, a ratio of 1.5 to less than 3.0, a weak responder, and a ratio of 3.0 or greater, a good responder.
3.  If the pre-vaccination concentration is greater than 1.0, it may be difficult to assess the response based on a ratio alone.  A post-vaccination concentration above 2.5 IU in this case is usually adequate.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

86317

Components
Component Test Code* Component Chart Name LOINC
0050535 Tetanus Antibody, IgG 53935-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Anti-tetanus toxoid IgG
  • C. tetani
  • Clostridium tetani
  • Tetanus Immune Response
  • Tetanus toxoid antibodies
  • Tetanus Vaccine Response
Tetanus Antibody, IgG